HCM Q1 2022 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena

HCMHUTCHMED (China) Limited

$3B

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$101M+23.9% YoY

Gross Profit

-$59M-57.9% margin

Operating Income

-$98M-97.4% margin

Net Income

-$81M-80.6% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

-26.9%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$53M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$342M

Stockholders' Equity

$800M

Cash & Equivalents

$468M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$101M	$82M	+23.9%
Gross Profit	-$59M	$17M	-452.1%
Operating Income	-$98M	-$63M	-55.7%
Net Income	-$81M	-$65M	-25.6%